studies

la/mBC - HR-positive - 2nd line (L2), ganitumab plus endocrine therapy vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsQUILT-2.015, 2013 1.78 [1.27; 2.50] 1.78[1.27; 2.50]QUILT-2.015, 201310%NAnot evaluable progression or deaths (PFS)detailed resultsQUILT-2.015, 2013 1.17 [0.91; 1.50] 1.17[0.91; 1.50]QUILT-2.015, 201310%156NAnot evaluable objective responses (ORR)detailed resultsQUILT-2.015, 2013 0.60 [0.15; 2.42] 0.60[0.15; 2.42]QUILT-2.015, 201310%95NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-18 12:40 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 353,358,359 - treatments: 1428

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons